Breast Cancer Clinical Trial
Official title:
EEG as a Predictor for Postoperative Pain and the Development of Chronic Postsurgical Pain After Breast Cancer Surgery
1. Rationale The inter-individual pain experience immediately after surgery is
considerable. In addition, a number of patients develop chronic post surgery pain
(CPSP). Patients undergoing surgery for breast cancer are at risk of developing both
acute post surgical pain as well as CPSP. Recently, in a group of patients with chronic
back pain, it was demonstrated how subjectively reported pain is associated with
specific electroencephalography (EEG) parameters, namely the N2 and P3 components of
the pain event-related potential (ERP). It was concluded that ERP was associated with
self-reported pain in daily life up to two weeks after the measurement. This resulted
in the current hypothesis that EEG may be a predictor for postoperative pain.
2. Study design Prospective cohort study. Within 2 weeks before surgery, 150 patients will
undergo an EEG measurement with five 'vulnerability' tasks. The experiment will be
repeated 6 months postoperatively.
Study population: Female patients with breast cancer who will undergo breast surgery,
between the ages of 18 to 65 years.
3. Main study parameters/endpoints Primary outcome is postoperative pain, measured in a
pain diary 4 days postoperatively. Secondary outcomes are development of chronic post
surgery pain and quality of life. The main goal is to develop a comprehensive
prediction model for acute and chronic postoperative pain after breast cancer surgery,
based on the EEG results of the five vulnerability experiments.
Status | Terminated |
Enrollment | 4 |
Est. completion date | February 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Age 18 - 65 years. - ASA 1-2. - Sufficient comprehension of the Dutch spoken and written language. - Elective curative breast cancer surgery, both mastectomy and breast- conserving therapy - Stage I and II breast cancer. - Written informed consent is obtained Exclusion Criteria: - Previous breast surgery, both ipsilateral and contralateral. - Stage III-IV breast cancer. - Chronic pain (>3months) with an average severity of at least a VAS score 4 during the last two weeks. - Chronic pain for which invasive treatment is needed. - Use of (weak / strong) opioids in the last week. - A history of opioid addiction. - Regular use of the following medications in the last year: antiepileptics,antipsychotics and anxiolytics. - ASA 3 or higher. - Consumption of alcohol (>4 units) and / or drugs the evening before. - Alcohol consumption (>= 5 units/day). - Illiteracy, problems with self expression, language barrier. - Serious vision and / or hearing problems, interfering the performance of the experimental tasks. - A history of psychiatric complaints and/or epilepsy . - A medical history of CVA or TIA. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastricht UMC | Maastricht | Limburg |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acute postoperative pain | VAS measured in a daily pain diary | during 4 days after surgery | No |
Secondary | Quality of Life | Quality of Life measured with SF-36 | within 2 weeks before surgery and at 3,6 and 12 months postoperatively | No |
Secondary | Development of chronic pain | Brief Pain Inventory | at 3,6 and 12 months postoperatively | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |